Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Feature

NVP-LAQ824 a novel histone deacetylase inhibitor

Target of the Month: November, 2003 Posted on: 19 Nov 03

Summary

The field of histone deacetylation continues to receive considerable interest principally due to the ability of histone deacetylase (HDAC) inhibitors to produce cytostatic activity in cancer, but more recently due to the role that this class has in other indications such as autoimmune disorders. Novartis researchers have now developed a HDAC inhibitor of greater anti-proliferative potency than that of SAHA, and which almost completely blocked the growth of human colon and lung cancer xenografts

The field of histone deacetylation continues to receive considerable interest due to the ability of histone deacetylase (HDAC) inhibitors to modulate transcriptional activity. Molecules from this therapeutic class have the potential to occupy an indomitable position in the fast-moving cytostatic market. One reason why HDAC inhibitors could play such a key role in this $2 billion market is that they are able to improve the efficacy of existing cytostatics (such as the retinoids - for a review click here). Moreover, for the first time, they are able to target the transcription of specific disease-causing genes, improving the therapeutic window of cancer therapies. More recently, HDAC inhibitors have been linked to other indications such as autoimmune disorders (click here). In response to the emergence of HDAC inhibitors as a major therapeutic class LeadDiscovery recently published one of the most comprehensive overview of the pharmaceutical potential of HDAC inhibitors (click here to access "Histone deacetylase inhibitors: Redefining pharmaceutical approaches to the treatment of cancer").

At the time of this report suberoylanilide hydroxamic acid (SAHA) was one of the most advanced candidate inhibitors. Key clinical data on SAHA was highlighted in our previous edition of TherapeuticAdvances (click here). In this edition we report important data regarding Novartisx new HDAC candidate, NVP-LAQ824.


The development of NVP-LAQ824 by a group led by Peter Atadja at Novartis (J Med Chem. 2003 Oct 9;46(21):4609-24) was based on the proposition that HDAC inhibitors should be composed of a zinc ligand coupled to a xspecificity elementx by a spacer. Several structural classes that met this model were identified through HTS of Novartisx chemistry library. Identification of the hit, NVP-LAK974, and subsequent optimization produced NVP-LAQ824. This molecule inhibited HDAC activity with an IC50 of 32nM and proliferation of cancer cell lines with IC50s of 10-150nM. The anti-proliferative potency is up to 200-fold greater than that of SAHA. In vivo, NVP-LAQ824 almost completely blocked the growth of both human colon and lung cancer xenografts at tolerable doses. Ongoing studies are being conducted to determine the HDAC isoform specificity of NVP-LAQ824 and clinical trials have also been initiated in patients with solid tumors or leukemia [more]

LeadDiscovery

Last updated on: 27/08/2010 11:40:18

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.